Innocan Pharma * Patent !? Without a doubt, InnoCan Pharma* (WKN: A2PSPW) CEO Iris Bincovich (almost in Elon Musk fashion) knows how to keep investors happy.
Without "cryptogrammatic" encryption, important developments are promised in a timely manner. Without getting really concrete, however, as a fan of the company one knows that fundamental progress has ALWAYS been made in response to these "leaks" without exception so far. In this case, too, one can probably expect "bombshell news" in the near future, in my opinion.
The share of InnoCan Pharma* (WKN: A2PSPW) could therefore be on the verge of a massive revaluation, which in my eyes should even be accompanied by gains in the 3-digit percentage range. A good case study is Alector, Inc. (Nasdaq: ALEC): the stock gained a whopping 57% after the company announced a collaboration with GlaxoSmithKline (LSE/NYSE: GSK) on two first-stage clinical drugs to treat neurodegenerative diseases.
Speaking of neurodegenerative diseases: InnoCan Pharma* (WKN: A2PSPW) CEO Iris Bincovich had repeatedly hinted that the liposome/CBD technology being explored was aimed at treating diseases of the central nervous system. So far, more specifics have been omitted, and as it now turns out, probably for a very good reason.
In recent tweets from InnoCan CEO Iris Bicovich, it has become increasingly clear that both researches, which are being conducted in the laboratory of the holder of Israel's highest scientific award (EMET Prize) (with Professor Chezy Barenholz), may have unearthed breakthrough findings that can then be published once they are patented. Then, on Thursday evening (just before the market closed), the meaningful statement from InnoCan Pharma* (WKN: A2PSPW) CEO Iris Bincovich:
We had a special meeting with Adv. Bat Ami Gotliv, our patent attorney. We are getting excellent initial results which may lead to our patent.
Qduelle: wallstreetonline